BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23065471)

  • 1. Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL).
    Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Lee SI; Kang HJ; Choi CW; Park J; Song MK; Kim HJ; Kwon JH; Kwak JY; Bae SH; Park BB; Do YR; Lee HS; Jeong SH; Suh C; Kim HJ
    Int J Hematol; 2012 Nov; 96(5):631-7. PubMed ID: 23065471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Kang HJ; Choi CW; Park J; Kim HJ; Kwon JH; Lee HS; Lee GW; Eom HS; Kwak JY; Lee WS; Suh C; Kim HJ
    Int J Hematol; 2010 Oct; 92(3):510-7. PubMed ID: 20838958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
    Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Kang HJ; Choi CW; Park J; Kim HJ; Kwon JH; Lee HS; Lee GW; Eom HS; Kwak JY; Suh C; Kim HJ
    Cancer Sci; 2010 Nov; 101(11):2443-7. PubMed ID: 20831770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Kwon HC; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Lee GW; Choi CW; Park J; Suh C; Kim HJ
    Ann Hematol; 2010 Jun; 89(6):563-8. PubMed ID: 20024551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma.
    Wu RY; Li YX; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Fang H; Ren H; Liu QF; Wang ZY; Qi SN; Lu NN; Chen B; Zhang XM; Zhou LQ; Liu XF; Yu ZH
    Am J Clin Oncol; 2014 Feb; 37(1):41-6. PubMed ID: 22992625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project.
    Nathwani BN; Anderson JR; Armitage JO; Cavalli F; Diebold J; Drachenberg MR; Harris NL; MacLennan KA; Müller-Hermelink HK; Ullrich FA; Weisenburger DD
    J Clin Oncol; 1999 Aug; 17(8):2486-92. PubMed ID: 10561313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of Upfront Therapy for Marginal Zone Lymphoma.
    Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marginal zone B-Cell lymphoma among primary B-Cell lymphoma of Waldeyer's ring: histopathologic and immunohistochemical study of 16 tonsillectomy specimens.
    Kojima M; Nakamura N; Shimizu K; Tamaki Y; Itoh H; Nakamura S
    Int J Surg Pathol; 2008 Apr; 16(2):164-70. PubMed ID: 18417673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Hodgkin's lymphoma of Waldeyer's ring.
    Albada J; Hordijk GJ; van Unnik JA; Dekker AW
    Cancer; 1985 Dec; 56(12):2911-3. PubMed ID: 3840405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
    Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
    Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary nodal marginal zone lymphomas of splenic and MALT type.
    Campo E; Miquel R; Krenacs L; Sorbara L; Raffeld M; Jaffe ES
    Am J Surg Pathol; 1999 Jan; 23(1):59-68. PubMed ID: 9888704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination.
    Arcaini L; Burcheri S; Rossi A; Passamonti F; Paulli M; Boveri E; Brusamolino E; Orlandi E; Molteni A; Pulsoni A; Cox MC; Orsucci L; Fabbri A; Frezzato M; Voso MT; Zaja F; Montanari F; Pascutto C; Morra E; Cortelazzo S; Lazzarino M
    Oncologist; 2006 Mar; 11(3):285-91. PubMed ID: 16549813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.
    Zhang T; Wu Y; Ju H; Meng J; Guo W; Ren G
    Cancer Med; 2020 Jan; 9(1):194-203. PubMed ID: 31733094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study.
    Koh MS; Kim WS; Kim SJ; Oh SY; Yoon DH; Lee SI; Hong J; Song MK; Shin HJ; Kwon JH; Kim HJ; Do YR; Suh C; Kim HJ
    Int J Hematol; 2015 Oct; 102(4):420-5. PubMed ID: 26210384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
    Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
    Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of radiotherapy in patients with limited diffuse large B-cell lymphoma of Waldeyer's ring in remission after R-CHOP immunochemotherapy.
    Li C; Ma X; Pan Z; Lv F; Xia Z; Xue K; Zhang Q; Ji D; Cao J; Hong X; Guo Y
    Leuk Res; 2018 Nov; 74():80-85. PubMed ID: 30316031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites.
    Kuper-Hommel MJ; van de Schans SA; Vreugdenhil G; van Krieken JH; Coebergh JW
    Leuk Lymphoma; 2013 Sep; 54(9):1891-7. PubMed ID: 23302044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Waldeyer's ring lymphomas: treatment results and prognostic factors.
    Gurkaynak M; Cengiz M; Akyurek S; Ozyar E; Atahan IL; Tekuzman G
    Am J Clin Oncol; 2003 Oct; 26(5):437-40. PubMed ID: 14528067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era.
    Gutiérrez-García G; Colomo L; Villamor N; Arenillas L; Martínez A; Cardesa T; García-Herrera A; Setoain X; Rodríguez S; Ghita G; Abrisqueta P; Giné E; Bosch F; Campo E; Montserrat E; López-Guillermo A
    Leuk Lymphoma; 2010 Jul; 51(7):1225-32. PubMed ID: 20497002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.